ArticleScientific reports2026
Topology constrained nonnegative matrix factorization for time varying omic expression.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deciphering disease-specific progression from low sample size, high-dimensional omic profiles remains challenging. Traditional biomarker discovery methods are costly and limited, while Nonnegative Matrix Factorization (NMF), though popular, suffers from instability and lack of biologically relevant solutions. This study aims to overcome these limitations by introducing a more robust framework. This article proposes TopConNMF, a topology-constrained extension of NMF which incorporates structural constraints, ensures stability, accuracy, and faster performance while maintaining biological interpretability. The method was evaluated on two publicly available time-varying omic datasets with established ground truths and compared against other state-of-the-art approaches. The TopConNMF consistently demonstrated stable performance across both the datasets, delivering superior accuracy and biologically relevant factorization compared to conventional NMF and other benchmark methods. The exhaustive evaluation confirmed its robustness in capturing disease-specific profiles and its efficiency in handling complex, high-dimensional data. Thus, TopConNMF provides a deeper understanding of complex biological systems by producing stable and interpretable factorization. Its broad applicability across multiple disease manifestations highlights its potential as a valuable tool for advancing omic data analysis and biomarker discovery. Clinical Impact: TopConNMF enables reliable biomarker discovery from limited omic data, supporting early diagnosis, patient stratification, and personalized treatment, thereby bridging computational findings with clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.